Exavir Therapeutics is focused on developing innovative ultra-long-acting medicines aimed at treating chronic viral infections and central nervous system (CNS) disorders. Their proprietary prodrug nanomedicine technology significantly enhances the pharmacokinetic properties of small molecule drugs, extending their half-life by over 100 times. This advancement is particularly crucial in the context of HIV treatment, where adherence to daily medication regimens is a significant challenge. Exavir's approach not only aims to improve patient compliance but also seeks to provide safer and more effective treatment options, thereby addressing the substantial healthcare costs associated with chronic viral infections.

The company’s platform includes the development of ultra-long-acting injectables and nanocrystal formulations that facilitate extended release and dosing intervals. This technology has the potential to impact a wide range of conditions, including HIV, opioid use disorder, and schizophrenia, with the goal of reaching nearly 100 million patients. Exavir's research has led to the creation of various long-acting prodrug formulations, such as those for tenofovir and dolutegravir, which have demonstrated promising results in achieving sustained therapeutic effects. By leveraging these advanced formulations, Exavir Therapeutics aims to transform the treatment landscape for chronic diseases, enhancing patient outcomes through improved medication adherence and convenience.

United States

Exavir Therapeutics is a biotechnology company dedicated to developing nanomedicines for chronic disorders in virology and CNS, beginning with ultra-long-acting integrase inhibitors for HIV Treatment and HIV PrEP.

Exavir Therapeutics

Company Details